论文部分内容阅读
目的 观察乙肝病毒血清标志物阳性恶性肿瘤患者化疗所致肝功能损害情况。方法 乙肝病毒血清标志物阳性恶性肿瘤患者336例,化疗2周后测肝功能(包括ALT、AST、ALP、GGT及TBIL),并选119例乙肝病毒标志物阴性恶性肿瘤患者作为对照。结果 乙肝病毒标志物阳性组肝功能异常比率(38.39％)显著高于对照组(19.33％)(P<0.01)。结论 乙肝病毒标志物阳性恶性肿瘤患者化疗时较易出现肝功能损害。
Objective To observe the liver damage induced by chemotherapy in patients with positive HBV-seropositive markers. Methods A total of 336 patients with positive HBV-seropositive markers were tested for liver function (including ALT, AST, ALP, GGT and TBIL) after 2 weeks of chemotherapy. 119 patients with negative HBV-negative malignant tumors were selected as controls. Results The rate of abnormal liver function (38.39%) in HBV positive group was significantly higher than that in control group (19.33%) (P <0.01). Conclusion Hepatitis B virus is more susceptible to liver damage in patients with positive malignant tumor.